How Does Bristol-Myers Squibb’s Oncology Drugs Portfolio Compare To Its Peers?

Bristol-Myers Squibb’s (NYSE:BMY) oncology drugs business is its largest therapeutic area, and it will likely grow in mid-single-digits from about $10.3 billion in 2018 to $12.4 billion in 2021, according to Trefis estimates. This growth will likely be driven by higher sales of Opdivo. In this analysis, we compare Bristol-Myers Squibb’s growth in oncology drugs’ sales vis-à-vis its primary competitors and provide an outlook of the future course of business. You can view our interactive dashboard analysis ~ How Does Bristol-Myers Squibb’s Oncology Drugs Portfolio Compare To Its Peers? ~ for more details. In addition, you can see more of Healthcare Data here.

Bristol-Myers Squibb’s Oncology Drugs Portfolio Revenue Is Bigger Than That of Johnson & Johnson, Merck, And Pfizer, But Much Smaller Than The Market Leader ~ Roche

• Average Annual Growth:
  • Roche: 3.6%
  • Bristol-Myers Squibb: 23.1%
  • Johnson & Johnson: 30.3%
  • Merck: 92.7%
  • Pfizer: 19.6%

Bristol-Myers Squibb’s Share In Oncology Drugs Market Could Grow As It May See Oncology Drugs Sales Growth At A Higher Pace When Compared To Some of Its Peers

• Combined oncology drugs revenue for Roche, Bristol-Myers Squibb, Johnson & Johnson, Merck, and Pfizer grew at an average annual rate of 18.0% from $45.4 billion in 2016 to $62.7 billion in 2018.
• Bristol-Myers Squibb’s share has grown from around 15% in 2016 to 16.5% in 2018, as it saw growth in oncology drugs’ sales at a higher pace when compared to growth for the overall combined market during the same period.
• Looking forward, this trend could continue with Bristol-Myers Squibb’s share increasing to 17.5%, as it is expected to continue to grow at a faster pace, when compared to overall market.

For Bristol-Myers Squibb It Is Opdivo All The Way Which Drives The Segment Sales

• Opdivo continues to do well for Bristol-Myers Squibb, and annual sales could grow to north of $8 billion over the next few years, given its positioning in lung cancer, which is the largest cancer market. However, Opdivo’s future growth largely depends on its further approvals for other indications, given the drug is facing stiff competition from Merck’s Keytruda, which has shown better results in recent studies.
• Sprycel could see a slowdown in sales, given its nearing its loss of market exclusivity next year, and it will likely face generic competition.
• Yervoy sales could also be impacted in coming years, due to Merck’s combination. Keynote-426 trial of Keytruda + Inlyta in first-line renal cell carcinoma showed 47% less risk of death, and this compares with data from CheckMate-214 of Opdivo + Yervoy, which showed 29% less risk of death.
• Empliciti hasn’t seen any significant growth in the recent years, and this trend could continue. The drug did receive another U.S. FDA approval last year for its combination with Pomalidomide and Dexamethasone, for certain patients with relapsed or refractory multiple myeloma, which could aid the drug’s sales.

Here Are The Key Patent Expiration Milestones For Bristol-Myers Squibb’s Oncology Drugs

• Opdivo: 2028 (US) 2030 (EU) 2031 (Japan)
• Yervoy: 2025 (US & Japan) 2026 (EU)
• Sprycel 2020 (US) 2021 (Japan)
• Empliciti 2029 (US, EU & Japan)

Oncology Drugs Also Account For Close To Half of Bristol-Myers Squibb’s Total Sales

• Bristol-Myers Squibb’s oncology drugs sales accounted for 35% of the company’s total revenues in 2016.
• The figure increased to 41% in 2017, and further to 46% in 2018. due to higher Opdivo sales.
• We expect the figure to be grow further to 52% in 2021, as the company’s other therapeutic areas, such as Anti-Infectious, and Immunology, and Mature Products could decline in the coming years, while oncology could continue to grow.

What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs

For CFOs and Finance Teams | Product, R&D, and Marketing Teams

All Trefis Data

Like our charts? Explore example interactive dashboards and create your own.